Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7711550 | 0.99 | MEN1 (0.66) | MEN1KMT2AMAPTTP53USP2 | |
| SCHEMBL7708510 | 0.91 | MEN1 (0.61) | MEN1KMT2AMAPTKCNH2CACNA1G | |
| Hydrochloric Acid SCHEMBL7711584 | 0.90 | MEN1 (0.63) | MEN1KMT2AMAPTSMN1; SMN2KCNH2 | |
| SCHEMBL7711663 | 0.89 | KMT2A (0.64) | MEN1KMT2AMAPTTP53USP2 | |
| SCHEMBL7705078 | 0.85 | MEN1 (0.61) | MEN1KMT2AMAPTKCNH2CACNA1G | |
| Hydrochloric Acid SCHEMBL7711666 | 0.84 | MEN1 (0.63) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL7713556 | 0.83 | MEN1 (0.64) | MEN1KMT2AMAPTTP53USP2 | |
| Hydrochloric Acid SCHEMBL7713489 | 0.82 | MEN1 (0.66) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL2021538 | 0.81 | MAPT (0.80) | MEN1KMT2AMAPTTP53USP2 | |
| SCHEMBL2021540 | 0.81 | MAPT (0.80) | MEN1KMT2AMAPTTP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6358515-B2 | ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION; TREATMENT OF GLAUCOMA | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | claimed |
| US-20010008893-A1 | HYDROQUINONE DERIVATIVES | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-19 | — | — | US | claimed |
| EP-0972766-A1 | HYDROQUINONE DERIVATIVES | Senju Pharmaceutical Co., Ltd. (JP) | 2000-01-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008893-A1 | HYDROQUINONE DERIVATIVES | REN, AGTR1, AGTR2 | MEN1 2775/4885KMT2A 2128/4885MAPT 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.